Băncilă, Diaconu și Asociații SPRL assisted the founders of CytoGenomic Medical Laboratory in the sale of a majority stake in CytoGenomic Medical Laboratory SRL, Romanian leading genetic laboratory and one of the most innovative providers of medical services, to FutureLife, an European leader in reproductive medicine.

Dr. Danae Stambouli, founder of CytoGenomic Medical Laboratory, will remain a significant shareholder and CEO, leading the company’s expansion strategy.

Danae Stambouli: “I am very pleased with the contribution of Băncilă, Diaconu și Asociații team to the completion of the transaction. I particularly appreciated their promptness, client-oriented approach, and commercial knowledge, which doubled their legal contribution and provided us with comfort throughout the negotiations.”

Alexandra Siminiceanu, Managing Associate at Băncilă, Diaconu și Asociații SPRL: “We thank the founders of CytoGenomic Medical Laboratory for the trust placed in us throughout this transaction, as well as for the opportunity to support the company’s development alongside a partner of the caliber of FutureLife.”

The Băncilă, Diaconu și Asociații SPRL team that assisted CytoGenomic Medical Laboratory in this transaction consisted of Radu Diaconu (Managing Partner), Ștefan Mantea (Director), Alexandra Siminiceanu (Managing Associate) and Miruna Coderie (Senior Associate).

About Băncilă, Diaconu și Asociații SPRL

Băncilă, Diaconu și Asociații SPRL (formerly Radu și Asociații SPRL) is a Romanian full-service law firm, offering both legal advisory services and assistance before the courts of law, with a significant tax policy and controversy (TPC) practice.

Băncilă, Diaconu și Asociatii SPRL is a member firm of Ernst & Young Global Ltd and part of the expanding EY Law global network, which has more than 2,400 lawyers and offices in over 90 jurisdictions.

Our expertise has been recognized by the market and international firm directories.

Chambers Global 2019 has recognized our Corporate/M&A practice while Chambers Europe 2019, 2020, 2021 and 2022 have placed our Tax Policy and Controversy practice on Band 1. The Legal 500 Europe, Middle East and Africa 2019, 2020, 2021 and 2022 have also ranked our Commercial, Corporate/M&A, Real Estate and Employment practices, while the 2020, 2021 and 2022 editions placed our Tax Policy and Controversy practice on Tier 1.